No abstract

The results obtained suggest that well-timed LVL-apheresis increased SC-yield in cell harvest, resulting in faster bone marrow repopulation and hematological reconstitution, as well as better overall clinical outcome of transplantation. These results necessitate additional examinations of CD34+ subsets ratio in cell harvest.

No abstract

No abstract

This article describes a LabVIEW-based implementation of remote control of laboratory equipment for basic Electronics courses. Remote control of laboratory equipment is demonstrated on an example of recording the amplitude characteristics of a T-notch filter. Overview of traditional, virtual, and remote laboratory features is given, too. Real laboratory setup is presented, including hardware and software components and virtual instruments, as well as solutions for remote laboratory access. Finally, the way of putting the laboratory online and the course of the experiment are shown. ß

No abstract

Improved cytoreductive potential of plateletapheresis in the treatment of thrombocythemia: a single center study Poboljšani citoreduktivni potencijal trombocitafereze u lečenju trombocitemije To the Editor: Extreme thrombocytosis (ETC; cell-count ≥ 1500  10 9 /L) in the essential thrombocythemia (ET) patients-with altered platelet (Plt) morphology/aggregability (Plt-dysfunction) and immature reticulated Plts-increases the risk of both thromboembolic and/or hemorrhagic events (up to 50%). The evidence-based clinical guideline for therapy of asymptomatic-ET (e.g., exact cytapheresis-threshold, target Plt-count, etc.) is not yet established. In the treatment of symptomatic-ET (when low-dose aspirin or other anti-Plt and the highest doses of chemotherapy are without rapid response or contraindicated, as in pregnancy), cytoreduction by plateletapheresis is useful or essential 1-4. The first cytapheresis in our Apheresis Center was performed in 1971 for treatment of pregnant women with hyperleukocyte-leukostasis 1, 2. The aim of this study was to evaluate cytoreductive potential of the Spectra-Optia/IDL-System, based upon the ex vivo Plt-removal and the in vivo Plt-depletion (Plt-removal/depletion) efficacy (using our modifications of manufacturer's original protocol). The Plt-removal/depletion efficacy of this study was compared to our earlier results (historical database) and the latest literature data for different devices. To the best of our knowledge, this is the second published clinical evaluation of the efficacy and safety of therapeutic plateletapheresis using the Spectra-Optia. In the treatment of a 68-year-old female patient suffering from symptomatic-ET (with headaches, vertigo, visualdisturbances and paresthesia) the Plt-removal/depletion procedure was performed by the Spectra-Optia/IDL-System (Terumo BCT; USA). Our modifications of apheresis protocol included the collection-preference and inlet flow corrections (altered collection speed) as well as an increase of the target cell suspension volume to improve the Plt-removal/depletion

Implanatation of BMMNC concomitant to CABG is a safe and feasible procedure that demonstates not only the improved functional capacity but also a reduced cardiac mortality in a 5-year follow-up in patients with ischemic cardiomyopathy scheduled for CABG surgery.